000			02317cam a2200349 a 4500
003			EG-GiCUC
005			20250223031126.0
008			141224s2014 ua d f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aPh.D
099			_aCai01.19.04.Ph.D.2014.Ib.R
100	0		_aIbrahim Abdelaziz Ibrahim Malash
245	1	0	_aRole of aberrant growth factor expression and cytochrome P2D6 polymorphism in endocrine resistance in breast cancer using the real time superarray technique / _cIbrahim Abdelaziz Ibrahim Malash ; Supervised Rabab Mohamed Gaafar , Sabry Mohamed Shaarawy , Osman Mohamed Mansour
246	1	5	_aدراسة آليات المقاومه للعلاج الهرمونى لدى مريضات سرطان الثدى و امكانية استحداث طرق جديده للعلاج
260			_aCairo : _bIbrahim Abdelaziz Ibrahim Malash , _c2014
300			_a138 P. : _bcharts ; _c25cm
502			_aThesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Oncology - Medical
520			_aIn an attempt to explore genetic factors behind resistance to tamoxifen and if possible targeting these factors or predicting response prior to therapy to avoid Tamoxifen in some patients who are expected to respond poorly to the drug. We prospectively studied the response to tamoxifen in braest cancer patients with measurable locally recurrent and / or metastatic hormone positive disease. We devided the patients into responsive and refractory groups according to response they showed to the drug. We studied the genetic profile of the groups to explore the effect of any genetc aberration that may be responsible for the degree of response to tamoxifen. Results showed that there is a statistically significant correlation between CYP2D6 mutations and resistance to tamoxifen P value = < 0.02
530			_aIssued also as CD
653		4	_aBreast cancer
653		4	_aCYP2D6 and gene profiling
653		4	_aHormone resistance
700	0		_aOsman Mohamed Mansour , _eSupervisor
700	0		_aRabab Mohamed Gaafar , _eSupervisor
700	0		_aSabry Mohamed Shaarawy , _eSupervisor
856			_uhttp://172.23.153.220/th.pdf
905			_aNazla _eRevisor
905			_aSamia _eCataloger
942			_2ddc _cTH
999			_c48906 _d48906